What is AstraZeneca's EBITDA margin?

Latest reported EBITDA margin for AstraZeneca (AZN) is 33.86% as of the trailing twelve months (TTM) ending March 31, 2026.

How has AstraZeneca EBITDA margin changed year-over-year?

AstraZeneca (AZN) EBITDA margin changed +5.2 percentage points year-over-year on the latest annual filing.

When did AstraZeneca EBITDA margin hit its highest annual value?

AstraZeneca EBITDA margin reached its highest annual value of 45.81% in 2011.

What was AstraZeneca EBITDA margin in 2024?

AstraZeneca (AZN) EBITDA margin in 2024 was 28.55%.

What was AstraZeneca EBITDA margin in 2025?

AstraZeneca (AZN) EBITDA margin in 2025 was 33.76%.

AstraZeneca (AZN) EBITDA Margin — Annual & Quarterly %

TTM

33.9%

YoY change

+5.21pp

Trough year (1992)

11.4%

Peak year (2011)

45.8%

EBITDA Margin history chart for AstraZeneca (AZN) from 1990 to 2025

Latest: 33.8%

EBITDA Margin change chart for AstraZeneca (AZN) from 1990 to 2025

Latest: +5.21pp

EBITDA Margin history table for AstraZeneca (AZN) from 1990 to 2025


2025	33.8%	+5.21pp	Dec 31, 2025	Feb 24, 2026
2024	28.6%	-0.75pp	Dec 31, 2024	Feb 18, 2025
2023	29.3%	+8.81pp	Dec 31, 2023	Dec 31, 2023
2022	20.5%	+6.82pp	Dec 31, 2022	Dec 31, 2022
2021	13.7%	-16.71pp	Dec 31, 2021	Dec 31, 2021
2020	30.4%	+2.85pp	Dec 31, 2020	Dec 31, 2020
2019	27.5%	-4.67pp	Dec 31, 2019	Dec 31, 2019
2018	32.2%	+2.71pp	Dec 31, 2018	Dec 31, 2018
2017	29.5%	-2.15pp	Dec 31, 2017	Dec 31, 2017
2016	31.6%	+3.46pp	Dec 31, 2016	Dec 31, 2016
2015	28.2%	+7.48pp	Dec 31, 2015	Dec 31, 2015
2014	20.7%	-11.64pp	Dec 31, 2014	Dec 31, 2014
2013	32.3%	-5.86pp	Dec 31, 2013	Dec 31, 2013
2012	38.2%	-7.62pp	Dec 31, 2012	Dec 31, 2012
2011	45.8%	+1.50pp	Dec 31, 2011	Dec 31, 2011
2010	44.3%	+1.79pp	Dec 31, 2010	Dec 31, 2010
2009	42.5%	+2.59pp	Dec 31, 2009	Dec 31, 2009
2008	39.9%	+6.27pp	Dec 31, 2008	Dec 31, 2008
2007	33.7%	-2.45pp	Dec 31, 2007	Dec 31, 2007
2006	36.1%	+3.42pp	Dec 31, 2006	Dec 31, 2006
2005	32.7%	+5.55pp	Dec 31, 2005	Dec 31, 2005
2004	27.1%	-0.98pp	Dec 31, 2004	Dec 31, 2004
2003	28.1%	+0.28pp	Dec 31, 2003	Dec 31, 2003
2002	27.8%	-2.60pp	Dec 31, 2002	Dec 31, 2002
2001	30.4%	+3.33pp	Dec 31, 2001	Dec 31, 2001
2000	27.1%	-2.62pp	Dec 31, 2000	Dec 31, 2000
1999	29.7%	+1.03pp	Dec 31, 1999	Dec 31, 1999
1998	28.7%	+2.55pp	Dec 31, 1998	Dec 31, 1998
1997	26.1%	+2.73pp	Dec 31, 1997	Dec 31, 1997
1996	23.4%	+5.56pp	Dec 31, 1996	Dec 31, 1996
1995	17.9%	-3.23pp	Dec 31, 1995	Dec 31, 1995
1994	21.1%	-0.12pp	Dec 31, 1994	Dec 31, 1994
1993	21.2%	+9.83pp	Dec 31, 1993	Dec 31, 1993
1992	11.4%	-11.45pp	Dec 31, 1992	Dec 31, 1992
1991	22.8%	+4.14pp	Dec 31, 1991	Dec 31, 1991
1990	18.7%	—	Dec 31, 1990	Dec 31, 1990

202533.8%+5.21pp
202428.6%-0.75pp
202329.3%+8.81pp
202220.5%+6.82pp
202113.7%-16.71pp
202030.4%+2.85pp
201927.5%-4.67pp
201832.2%+2.71pp
201729.5%-2.15pp
201631.6%+3.46pp
201528.2%+7.48pp
201420.7%-11.64pp
201332.3%-5.86pp
201238.2%-7.62pp
201145.8%+1.50pp
201044.3%+1.79pp
200942.5%+2.59pp
200839.9%+6.27pp
200733.7%-2.45pp
200636.1%+3.42pp
200532.7%+5.55pp
200427.1%-0.98pp
200328.1%+0.28pp
200227.8%-2.60pp
200130.4%+3.33pp
200027.1%-2.62pp
199929.7%+1.03pp
199828.7%+2.55pp
199726.1%+2.73pp
199623.4%+5.56pp
199517.9%-3.23pp
199421.1%-0.12pp
199321.2%+9.83pp
199211.4%-11.45pp
199122.8%+4.14pp
199018.7%—

EBITDA Margin values are taken from AstraZeneca's reported income statements (interim 6-K and annual 20-F filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA Margin at AstraZeneca (AZN)

According to AstraZeneca's latest reported financial statements, the company's latest reported EBITDA margin is 33.9%. EBITDA margin is EBITDA divided by revenue — earnings before interest, taxes, depreciation, and amortization as a percentage of sales. By stripping out non-cash charges and capital-structure effects, it approximates operating cash profitability and is widely used to compare companies with different asset bases and leverage.

Headline figure above is from the reporting period ending March 31, 2026 (reported April 29, 2026). Chart and table below cover the full reported history back to 1990.

2025's annual EBITDA margin for AstraZeneca (AZN) came in at 33.76% – expanded 5.2 percentage points year-over-year.

The record annual EBITDA margin stands at 45.81%, reached in 2011; the historical low of 11.38% was recorded in 1992.

AstraZeneca EBITDA Margin by Year

AstraZeneca EBITDA Margin 2025: 33.8%

AstraZeneca posted EBITDA margin of 33.76% in 2025, expanded 5.2 percentage points from 2024.

AstraZeneca EBITDA Margin 2024: 28.6%

In 2024, AstraZeneca reported EBITDA margin of 28.55%, contracted 0.7 percentage points from 2023.

AstraZeneca EBITDA Margin 2023: 29.3%

AstraZeneca EBITDA margin in 2023 was 29.30%, expanded 8.8 percentage points from 2022.

AstraZeneca EBITDA Margin 2022: 20.5%

2022's EBITDA margin for AstraZeneca came in at 20.48%, expanded 6.8 percentage points from 2021.

AstraZeneca EBITDA Margin 2021: 13.7%

AstraZeneca EBITDA margin in 2021 was 13.66%.

See more financial history for AstraZeneca (AZN).

Sector peers by EBITDA Margin

Healthcare peers of AstraZeneca (AZN), ranked by their latest EBITDA margin


Novo Nordisk (NVO)	55.4%
Amgen (AMGN)	46.6%
Eli Lilly (LLY)	45.9%
Merck & Co. (MRK)	34.6%
Johnson & Johnson (JNJ)	30.3%
AbbVie (ABBV)	26.9%
Thermo Fisher Scientific (TMO)	24.7%
UnitedHealth Group (UNH)	5.1%

Frequently asked questions

AstraZeneca (AZN) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation